Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world camrelizumab monotherapy in hepatocellular carcinoma
ChiCTR2000041405Phase 4Recruiting
- Sponsor
- Mengchao Hepatobiliary Hospital of Fujian Medical University
- Start
- Jun 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in hepatocellular carcinoma (HCC), sponsored by Mengchao Hepatobiliary Hospital of Fujian Medical University. Primary endpoint: Progression-free survival. Started Jun 2020; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000041405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041405.